Benjamin P. Sandvik

Array ( [id] => 18075964 [patent_doc_number] => 20220401576 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => GOLD NANOPARTICLES/NANOSHELLS IMMUNE CONJUGATES FOR ENHANCED IMMUNOTHERAPY AND PHOTOTHERMAL THERAPY FOR HEMATOLOGIC MALIGNANCIES [patent_app_type] => utility [patent_app_number] => 17/773519 [patent_app_country] => US [patent_app_date] => 2020-11-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9931 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773519 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18013315 [patent_doc_number] => 11505597 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-11-22 [patent_title] => Middle east respiratory syndrome coronavirus neutralizing antibodies and methods of use thereof [patent_app_type] => utility [patent_app_number] => 17/082865 [patent_app_country] => US [patent_app_date] => 2020-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 22080 [patent_no_of_claims] => 33 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17082865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16778418 [patent_doc_number] => 20210115496 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-22 [patent_title] => Methods and Devices for Real-Time Diagnostic Testing (RDT) for Ebola and other Infectious Diseases [patent_app_type] => utility [patent_app_number] => 17/067257 [patent_app_country] => US [patent_app_date] => 2020-10-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 29970 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17067257 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16726536 [patent_doc_number] => 20210093683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-01 [patent_title] => HERPES 2 ANTIBODY SYSTEM [patent_app_type] => utility [patent_app_number] => 17/063715 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3276 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063715 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16748848 [patent_doc_number] => 20210100857 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-04-08 [patent_title] => HERPES 1 ANTIBODY SYSTEM [patent_app_type] => utility [patent_app_number] => 17/063706 [patent_app_country] => US [patent_app_date] => 2020-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 3189 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 96 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17063706 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18071432 [patent_doc_number] => 11530255 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-12-20 [patent_title] => Human antibodies to Ebola virus glycoprotein [patent_app_type] => utility [patent_app_number] => 17/039557 [patent_app_country] => US [patent_app_date] => 2020-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 28474 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 383 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17039557 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18825439 [patent_doc_number] => 11840710 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-12 [patent_title] => Methods for purification of recombinant AAV vectors [patent_app_type] => utility [patent_app_number] => 17/035480 [patent_app_country] => US [patent_app_date] => 2020-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19198 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17035480 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17983853 [patent_doc_number] => 20220349889 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-03 [patent_title] => IMMUNOASSAY FOR HEPATITIS B VIRUS CORE-RELATED ANTIGEN AND KIT THEREFOR [patent_app_type] => utility [patent_app_number] => 17/763687 [patent_app_country] => US [patent_app_date] => 2020-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12625 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763687 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990501 [patent_doc_number] => 20220356538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => HEPATITIS B VIRUS MUTANTS WITH INCREASED COVALENTLY CLOSED CIRCULAR DNA [patent_app_type] => utility [patent_app_number] => 17/763109 [patent_app_country] => US [patent_app_date] => 2020-09-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7915 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17763109 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16704369 [patent_doc_number] => 10954289 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-03-23 [patent_title] => Anti-SARS-CoV-2-spike glycoprotein antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 17/021286 [patent_app_country] => US [patent_app_date] => 2020-09-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 17 [patent_no_of_words] => 45362 [patent_no_of_claims] => 28 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17021286 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17858564 [patent_doc_number] => 11439702 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-09-13 [patent_title] => Influenza peptides and compositions [patent_app_type] => utility [patent_app_number] => 17/013000 [patent_app_country] => US [patent_app_date] => 2020-09-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 12 [patent_no_of_words] => 18504 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 272 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17013000 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16671389 [patent_doc_number] => 20210060152 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-04 [patent_title] => MULTIPLE MOSQUITO-BORNE FLAVIVIRUS VACCINE AND USE THEREOF IN INDUCING NEUTRALIZING ANTIBODIES [patent_app_type] => utility [patent_app_number] => 17/011140 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 1919 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 31 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011140 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16720110 [patent_doc_number] => 20210087257 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-03-25 [patent_title] => HUMAN CYTOMEGALOVIRUS NEUTRALIZING ANTIBODIES AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/011934 [patent_app_country] => US [patent_app_date] => 2020-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24038 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17011934 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17865408 [patent_doc_number] => 20220288143 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-15 [patent_title] => PHARMACEUTICAL COMPOSITION FOR TREATING CANCER, COMPRISING VACCINIA VIRUS AND GRANULOPOIESIS INHIBITOR AS ACTIVE INGREDIENTS [patent_app_type] => utility [patent_app_number] => 17/638750 [patent_app_country] => US [patent_app_date] => 2020-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19690 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17638750 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16511623 [patent_doc_number] => 20200390880 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-17 [patent_title] => Filovirus Consensus Antigens, Nucleic Acid Constructs And Vaccines Made Therefrom, And Methods Of Using Same [patent_app_type] => utility [patent_app_number] => 17/004818 [patent_app_country] => US [patent_app_date] => 2020-08-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -37 [patent_words_short_claim] => 324 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17004818 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17665533 [patent_doc_number] => 11359214 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-06-14 [patent_title] => Simian (gorilla) adenovirus or adenoviral vectors and methods of use [patent_app_type] => utility [patent_app_number] => 17/002064 [patent_app_country] => US [patent_app_date] => 2020-08-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13783 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17002064 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16506433 [patent_doc_number] => 20200385689 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-12-10 [patent_title] => SCALABLE PRODUCTION METHOD FOR AAV [patent_app_type] => utility [patent_app_number] => 16/998548 [patent_app_country] => US [patent_app_date] => 2020-08-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7834 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 48 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16998548 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16756602 [patent_doc_number] => 10975139 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2021-04-13 [patent_title] => Anti-SARS-CoV-2-Spike glycoprotein antibodies and antigen-binding fragments [patent_app_type] => utility [patent_app_number] => 16/996297 [patent_app_country] => US [patent_app_date] => 2020-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 17 [patent_no_of_words] => 45397 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16996297 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18281618 [patent_doc_number] => 20230097090 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-30 [patent_title] => IMPROVED LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 17/634516 [patent_app_country] => US [patent_app_date] => 2020-08-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 65190 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -63 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17634516 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17400895 [patent_doc_number] => 20220042985 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => SARS-CoV-2 IgG/IgM ANTI-BODY DETECTION KIT [patent_app_type] => utility [patent_app_number] => 16/987049 [patent_app_country] => US [patent_app_date] => 2020-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5047 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 99 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16987049 [rel_patent_id] =>[rel_patent_doc_number] =>)